Clinical trials

Products for assessing cognitive safety

Assess cognitive safety in Phase I

CTIS-Profile 2+ 
Evaluate cognitive safety in Phase II, III and IV

CTIS-Abuse Liability
Measure the potential for human abuse liability in clinical studies

Cognitive safety and pharmacovigilance

Accurately assess the cognitive safety and tolerability of compounds throughout clinical development with the Clinical Trial Information Systems on CANTAB Connect.

All drugs that cross the blood-brain barrier can impact cognitive function. Determining the cognitive safety properties of compounds reduces commercial risk of trials in compliance with regulatory guidance. 

Guide to cognitive safety and  tolerability products Assessing cognitive safety in clinical trials white paper

Read more about cognitive safety in clinical drug development in this article published in Drug Discovery Today.